Awad Atheer, Madla Christine M, McCoubrey Laura E, Ferraro Fabiana, Gavins Francesca K H, Buanz Asma, Gaisford Simon, Orlu Mine, Siepmann Florence, Siepmann Juergen, Basit Abdul W
29 - 39 Brunswick Square, UCL School of Pharmacy, University College London, London WC1N 1AX, United Kingdom.
Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
Adv Drug Deliv Rev. 2022 Feb;181:114076. doi: 10.1016/j.addr.2021.114076. Epub 2021 Dec 7.
Targeted drug delivery to the colon offers a myriad of benefits, including treatment of local diseases, direct access to unique therapeutic targets and the potential for increasing systemic drug bioavailability and efficacy. Although a range of traditional colonic delivery technologies are available, these systems exhibit inconsistent drug release due to physiological variability between and within individuals, which may be further exacerbated by underlying disease states. In recent years, significant translational and commercial advances have been made with the introduction of new technologies that incorporate independent multi-stimuli release mechanisms (pH and/or microbiota-dependent release). Harnessing these advanced technologies offers new possibilities for drug delivery via the colon, including the delivery of biopharmaceuticals, vaccines, nutrients, and microbiome therapeutics for the treatment of both local and systemic diseases. This review details the latest advances in colonic drug delivery, with an emphasis on emerging therapeutic opportunities and clinical technology translation.
靶向药物递送至结肠具有诸多益处，包括治疗局部疾病、直接作用于独特的治疗靶点以及提高全身药物生物利用度和疗效的潜力。尽管有一系列传统的结肠给药技术，但由于个体之间和个体内部的生理差异，这些系统的药物释放不一致，潜在疾病状态可能会进一步加剧这种情况。近年来，随着引入包含独立多刺激释放机制（pH和/或微生物群依赖性释放）的新技术，在转化和商业方面取得了重大进展。利用这些先进技术为通过结肠给药提供了新的可能性，包括递送生物制药、疫苗、营养物质和微生物组疗法以治疗局部和全身性疾病。本综述详细介绍了结肠给药的最新进展，重点是新兴的治疗机会和临床技术转化。
